Abstract
Gemfibrozil-statin combination therapy is a well-known risk factor for myopathy and rhabdomyolysis. Cerivastatin is a currently available statin with dual elimination; it is therefore expected to cause less drug-drug interaction. This case is the second reported case with severe rhabdomyolysis caused by cerivastatin-gemfibrozil combination. Moreover, in this case, the rhabdomyolysis was more severe and caused severe renal failure and death. The authors discuss how these drugs cause rhabdomyolysis and how rhabdomyolysis can cause renal failure.
MeSH terms
-
Diabetes Mellitus / drug therapy
-
Drug Interactions
-
Drug Therapy, Combination
-
Electrocardiography
-
Fatal Outcome
-
Gemfibrozil / adverse effects*
-
Gemfibrozil / therapeutic use
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
-
Hyperlipidemias / drug therapy
-
Hypolipidemic Agents / adverse effects*
-
Hypolipidemic Agents / therapeutic use
-
Male
-
Middle Aged
-
Myocardial Ischemia / drug therapy
-
Pyridines / adverse effects*
-
Pyridines / therapeutic use
-
Renal Dialysis
-
Renal Insufficiency / chemically induced*
-
Renal Insufficiency / therapy
-
Rhabdomyolysis / chemically induced*
-
Rhabdomyolysis / complications
-
Rhabdomyolysis / therapy
Substances
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Hypolipidemic Agents
-
Pyridines
-
cerivastatin
-
Gemfibrozil